首页> 中文期刊> 《中国药理学通报》 >姜黄素逆转非小细胞肺癌分子靶向药物耐药的研究进展

姜黄素逆转非小细胞肺癌分子靶向药物耐药的研究进展

         

摘要

In recent years,molecular biology has rapidly devel-oped,and molecular targeted therapy of non-small cell lung cancer has become a hot spot for the research. Although the tar-geted therapy has a big advantage compared with traditional chemotherapy,it is inevitable to encounter drug resistance in targeted therapy. Therefore,drug resistance has become the sig-nificant obstacle of targeted drugs for the treatment of non-small-cell lung cancer(NSCLC). Curcumin is the main extract of tu-meric rhizome,which harbours a wide range of antitumor activi-ties,and several studies have identified that curcumin exhibits reversion drug resistance against a variety of cancer cells. How-ever,there are few studies on curcumin reversion molecular tar-geted drug resistance. This review summarizes the recent pro-gress in resistance mechanism of targeted drug and the reversion resistance of curcumin.%近年来,随着分子生物学的飞速发展,非小细胞肺癌(NSCLC)的分子靶向治疗成为研究的热点.靶向治疗相对于传统化疗具有很大优势,但是在进行靶向治疗过程中不可避免地遇到耐药问题.耐药问题成为了靶向药物对NSCLC患者治疗的重大障碍.姜黄素是姜黄植物根茎提取物的主要活性成分,具有广泛的抗肿瘤等药理活性,一些研究已证实姜黄素能对许多肿瘤的耐药具有逆转作用.然而,姜黄素对靶向药物耐药的逆转作用的报道并不多.该文总结了国内外相关文献,对靶向药物的主要耐药机制和姜黄素对其耐药的相关作用研究进展进行综述.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号